In a small clean room tucked into the back of San Diego–based startup Organovo, Chirag Khatiwala is building a thin layer of human skeletal muscle. He inserts a cartridge of specially prepared muscle cells into a 3-D printer, which then deposits them in uniform, closely spaced lines in a petri dish. This arrangement allows the cells to grow and interact until they form working muscle tissue that is nearly indistinguishable from something removed from a human subject.
The technology could fill a critical need. Many potential drugs that seem promising when tested in cell cultures or animals fail in clinical trials because cultures and animals are very different from human tissue. Because Organovo’s product is so similar to human tissue, it could help researchers identify drugs that will fail long before they reach clinical trials, potentially saving drug companies billions of dollars. So far, Organovo has built tissue of several types, including cardiac muscle, lung, and blood vessels.
Unlike some experimental approaches that have used ink-jet printers to deposit cells, Organovo’s technology enables cells to interact with each other much the way they do in the body. They are packed tightly together and incubated, prompting them to adhere to each other and trade chemical signals. When they’re printed, the cells are kept bunched together in a paste that helps them grow, migrate, and align themselves properly. Muscle cells, for example, orient themselves in the same direction to create tissue that can contract.
So far, Organovo has made only small pieces of tissue, but its ultimate goal is to use its 3-D printer to make complete organs for transplants. Because the organs would be printed from a patient’s own cells, there would be less danger of rejection.
Organovo plans to fund its organ-printing research with revenue from printing tissues to aid in drug development. The company is undertaking experiments to prove that its technology can help researchers detect drug toxicity earlier than is possible with other tests, and it is setting up partnerships with major companies, starting with the drug giant Pfizer.
Geoffrey Hinton tells us why he’s now scared of the tech he helped build
“I have suddenly switched my views on whether these things are going to be more intelligent than us.”
ChatGPT is going to change education, not destroy it
The narrative around cheating students doesn’t tell the whole story. Meet the teachers who think generative AI could actually make learning better.
Meet the people who use Notion to plan their whole lives
The workplace tool’s appeal extends far beyond organizing work projects. Many users find it’s just as useful for managing their free time.
Learning to code isn’t enough
Historically, learn-to-code efforts have provided opportunities for the few, but new efforts are aiming to be inclusive.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.